MD-ENVIVA
14.9.2022 17:50:36 CEST | Business Wire | Press release
Today, the European Parliament once again voted to recognize primary woody biomass as a renewable energy source. This is consistent with its prior classification under both the first Renewable Energy Directive (RED) and RED II. Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced woody biomass, welcomes the designation as it marks a critical step in the right direction toward more low-carbon, drop-in alternatives to fossil fuels for power and heat generation, as part of an all-in renewables strategy to reduce carbon emissions and limit global dependence on fossil fuels.
Primary woody biomass is an essential renewable energy source for meeting the ambition sought by the EU Parliament to increase renewable energy to 45 percent by 2030, and for achieving the EU’s goal of carbon neutrality by 2050. In the words of Markus Pieper, the Member of Parliament leading on RED III, at the press conference held following the results of the plenary, “We do need wood-based biomass as a source of energy if we genuinely are to undertake this energy transition.”
The Parliament’s vote this week brings its position considerably closer to those of the Council and EU Commission by recognizing primary woody biomass as renewable, ensuring its continued zero-carbon rating in the EU Emissions Trading Scheme, and allowing its use to increase in volume.
“One thing is clear: wood-based biomass is a building block of the energy transition and, despite the vote of left-green Members of the European Parliament, can still be counted as renewable energy. The new directive will set the necessary framework to achieve the greatest possible CO2 reduction effect and not to ensure that our forests are burned in the future. I am counting on the member states to follow our proposals as the procedure progresses (“trilogue”),” continued Mr. Pieper in his statement.
The Council and EU Commission have continued their steadfast support for primary woody biomass and for its increased utilization to deliver climate change benefits and security of energy supply. Today’s vote serves as an initial negotiating position in the European Union’s process. After this vote, the EU Parliament, the Council of the EU, and the EU Commission will begin trilogue discussions, which are negotiations among the three parties, that are estimated to reach a final compromise on RED III in the first half of 2023.
“Heading into trilogues, the EU Parliament brought its position one step closer towards the mainstream views of the Council and the Commission, and away from the earlier minority position taken by the ENVI committee.
“While the process is foreign to those of us in the U.S., as an Austrian native, I can appreciate the complex nature of the EU legislative process, and that a compromise needs to be reached in trilogue negotiations to address the energy transition, security, and affordability crisis facing the EU. Today, biomass accounts for almost 60 percent of renewable energy in Europe.
“All serious pathways for achieving climate neutrality show that the use of bioenergy must and can be increased sustainably. The EU Commission’s own impact assessment for RED III outlines a need to increase bioenergy use from 2030 to 2050 by an average of 69 percent to provide vital grid balancing services, high temperature heat for industry, advanced biofuels, and negative emissions,” said Thomas Meth, President of Enviva.
“A failure to increase woody biomass use in the EU would mean failure in meeting climate goals, increased cost to EU consumers, and further disruption to security of energy supply on the brink of winter, when bioenergy makes up 25 percent of European heating supply and when incremental investments in more woody biomass infrastructure are desperately needed. At Enviva, we are encouraged by the progress made and are confident that a pragmatic and reasonable outcome will be reached,” concluded Meth.
About Enviva
Enviva Inc. (NYSE: EVA) is the world’s largest producer of industrial wood pellets, a renewable and sustainable energy source produced by aggregating a natural resource, wood fiber, and processing it into a transportable form, wood pellets. Enviva owns and operates ten plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi, and is constructing its 11th plant in Epes, Alabama. Enviva sells most of its wood pellets through long-term, take-or-pay off-take contracts with creditworthy customers in the United Kingdom, the European Union, and Japan, helping to accelerate the energy transition and to decarbonize hard-to-abate sectors like steel, cement, lime, chemicals, and aviation fuels. Enviva exports its wood pellets to global markets through its deep-water marine terminals at the Port of Chesapeake, Virginia, the Port of Wilmington, North Carolina, and the Port of Pascagoula, Mississippi, and from third-party deep-water marine terminals in Savannah, Georgia, Mobile, Alabama, and Panama City, Florida.
To learn more about Enviva, please visit our website at www.envivabiomass.com. Follow Enviva on social media @Enviva.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
